Market Research Logo

Amgen: Strong growth company with a challenging future

Amgen: Strong growth company with a challenging future

Introduction

Since it was founded in 1980, Amgen has established itself as a leading global biotechnology company and built increasingly strong human therapeutics brands as well as state of the art manufacturing facilities. This case study analyses the company's recent financial performance, evaluates the strategies that have helped it become a global leader, and explores what the future may hold.

Features and benefits

  • Investigation of Amgen’s success and a detailed analysis of its rise to be one of the most innovative biotechnology companies in the world.
  • Parallel comparisons in terms of R&D, stock market and financial performance to identify its strengths and weaknesses among its peers.
  • Analysis of the challenges that Amgen faces both internally and externally.
  • The case study also focuses on the R&D and acquisition strategy of the company.
Highlights
  • Since it was founded by William K. (Bill) Bowes and associates in 1980, Amgen has grown into a $120 billion company in just 35 years, generating significant profit in the process. The company’s impressive financial numbers have generated excellent share price performance, but the company does face a number of challenges.
  • Amgen has not only enjoyed rapid organic growth due to its excellent R&D, a number of valuable acquisitions have also been proven to be instrumental to its expansion in terms of product portfolio and revenue over the years. This strategy remains a central part of the company’s plans.
Your key questions answered
  • How did Amgen become the world's leading Biotechnology company?
  • What are the key challenges the company now faces?


OVERVIEW
Catalyst
Summary
CONSISTENT GROWTH ACCOMPANIED WITH SIGNIFICANT CHALLENGES
AMGen to Amgen
Rapid growing, profitable multi-billion dollar business
Profitable growth
Reliance on Neulasta and ENBREL
Dependence on North America
Strong stock market performance
FOCUSED AND WELL-MANAGED R&D
Amgen: An innovative human therapeutics company
Organic growth stimulated by committed R&D investment
Acquisitions continues to reap great results
BOTH INTERNAL AND EXTERNAL CHALLENGES AHEAHD
Challenges within the organization
Inability to produce blockbuster drugs
Litigation settlements hurt Amgen’s financial performance
Difficult external challenges ahead
Problematic acquisition
The rise of Gilead
CONCLUSIONS
Opportunity coincides with challenge for Amgen
APPENDIX
Definitions
Sources
Further Reading
Ask the analyst
About MarketLine
Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report